Lichtenstein, Kenneth A <br/><br/>
A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.  [electronic resource] 

 -  Antiviral therapy  2012 
 - 1301-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2040-2058 
<br/><br/><label>Standard No.: </label>10.3851/IMP2350  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antiretroviral Therapy, Highly Active--methods<br/>Biomarkers--metabolism<br/>CD4-CD8 Ratio<br/>CD4-Positive T-Lymphocytes--immunology<br/>CD8-Positive T-Lymphocytes--immunology<br/>Chemokine CCL5--metabolism<br/>Disease Progression<br/>Female<br/>HIV Infections--drug therapy<br/>HIV-1--pathogenicity<br/>Humans<br/>Immunologic Memory<br/>Inflammation--immunology<br/>Inflammation Mediators--immunology<br/>Lymphocyte Activation<br/>Male<br/>Middle Aged<br/>Pilot Projects<br/>Pyrrolidinones--pharmacology<br/>Raltegravir Potassium<br/>Viral Load<br/>gag Gene Products, Human Immunodeficiency Virus--immunology<br/>nef Gene Products, Human Immunodeficiency Virus--immunology